Summary
Former US President Trump's proposed 200% tariff on imported generic drugs, set to begin in 2028, could impact India's $9.7 billion pharmaceutical exports, though Indian firms have a two-year window to adapt. The industry states that reshoring drug manufacturing is not practical, and American patients and insurers may face increased healthcare costs.